Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

William Blair analysts cut AbbVie’s FY2025 earnings estimate to $11.82 per share from $12.21, citing revised outlooks. Other ...

Singapore, July 16: AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation ...

A federal court in Missouri has dismissed a legal challenge by drugmaker AbbVie to the state’s new 340B contract pharmacy law, which aims to regulate how pharmaceutical companies interact with ...

This was the stock's third consecutive day of losses.

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

AbbVie’s ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early July. The 50-day ...

Under [the plaintiffs'] reading, virtually all pharmaceutical product-support services would qualify as a kickback,” U.S.

AbbVie has updated its 2025 earnings guidance after taking an $823 million acquired in-process R&D (IPR&D) expense in Q2.

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.